Ardian-backed Riemser buys Zaltan

Zaltan will be fully integrated in the Riemser group and operate under the name Riemser Iberia. The company will support the expansion and penetration of Riemser in the Spanish market and the launch of new products in Iberia. Through the acquisition of Zaltan, Spain will become the fourth core market for the group.

Ardian bought a majority stake in Riemser in August 2012 from the company's founding family and minority investors, including TVM Capital.

This is the third bolt-on inked by the company, following its acquisitions of France-based Keocyt in 2014 and the purchase of British pharma specialist Intrapharm in 2015.

Headquarted in Berlin, Riemser focuses on the sales, marketing and lifecycle management of prescription-only human pharmaceuticals. Its products are used in a broad range of therapeutic areas, such as oncology, infectiology, neurology, dermatology and rheumatology.

Company 
Founded in 2017 and headquartered in Madrid, Zaltan specialises in the multichannel commercialisation, distribution and marketing of a wide range of speciality pharmaceuticals, with a focus on oncology, pain medicine and urology. The company employs 20 staff.

People
Riemser - Konstantin von Alvensleben (CEO).
Zaltanpharma - Enrique Remezal (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Portfolio management
• Southern Europe
• Healthcare
• DACH
• Ardian (formerly Axa PE)
• Germany
• Spain
• Build-up
• Buy-and-build